These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 21604594)

  • 1. [Deviating from classical triple therapy. Nuke sparing concepts as interest focus].
    MMW Fortschr Med; 2011 May; 153(18):38. PubMed ID: 21604594
    [No Abstract]   [Full Text] [Related]  

  • 2. What does the term "HIV-associated lipodystrophy" mean?
    Marcason W
    J Am Diet Assoc; 2009 Feb; 109(2):364. PubMed ID: 19167963
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of zidovudine in development of lipoatrophy.
    Moyle GJ
    AIDS Read; 2005 Nov; 15(11):591-4, 599-600, 603. PubMed ID: 16329181
    [No Abstract]   [Full Text] [Related]  

  • 4. [Prevention and therapy of HIV-associated lipodystrophy syndrome and antiretroviral caused metabolic changes].
    Mauss S
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():49-53. PubMed ID: 16385875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stavudine in antiretroviral therapy: is this the end?
    Brinkman K
    AIDS; 2009 Aug; 23(13):1727-9. PubMed ID: 19571724
    [No Abstract]   [Full Text] [Related]  

  • 6. Beyond lipodystrophy: will toxicity issues ever outweigh the benefits of HAART?
    Vella S; Palmisano L
    J HIV Ther; 2003 May; 8(2):27-8. PubMed ID: 15587479
    [No Abstract]   [Full Text] [Related]  

  • 7. Current insights into reverse transcriptase inhibitor-associated resistance.
    Wainberg MA; White AJ
    Antivir Ther; 2001; 6 Suppl 2():11-9. PubMed ID: 11678474
    [No Abstract]   [Full Text] [Related]  

  • 8. [Stigmatization, metabolic trouble, drug resistance: current challenges in HIV therapy].
    Mauss S; Jablonowski H
    MMW Fortschr Med; 2009 Apr; 151(18):28. PubMed ID: 19769068
    [No Abstract]   [Full Text] [Related]  

  • 9. Developing countries need better antiretroviral drugs.
    Mykén N; Sundbeck B; Mpumilwa G; Andersson R
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(1):23-4. PubMed ID: 19171914
    [No Abstract]   [Full Text] [Related]  

  • 10. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
    Negredo E; Paredes R; Bonjoch A; Tuldrà A; Fumaz CR; Gel S; Garcés B; Johnston S; Arnó A; Balagué M; Jou A; Tural C; Sirera G; Romeu J; Cruz L; Francia E; Domingo P; Arrizabalaga J; Ruiz I; Arribas JR; Ruiz L; Clotet B
    Antivir Ther; 1999; 4 Suppl 3():23-8. PubMed ID: 16021868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on mitochondrial toxicity of antiretrovirals and its link to lipodystrophy.
    McComsey G
    AIDS Rev; 2002; 4(3):140-7. PubMed ID: 12416448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleoside analogues toxicities related to mitochondrial dysfunction: focus on HIV-infected children.
    Viganò A; Giacomet V
    Antivir Ther; 2005; 10 Suppl 2():M53-64. PubMed ID: 16152706
    [No Abstract]   [Full Text] [Related]  

  • 13. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors.
    Introcaso CE; Hines JM; Kovarik CL
    J Am Acad Dermatol; 2010 Oct; 63(4):549-61; quiz 561-2. PubMed ID: 20846563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nucleoside analogues in 2008.
    Warwick Z; Churchill D
    J HIV Ther; 2008 Mar; 13(1):3-8. PubMed ID: 18953267
    [No Abstract]   [Full Text] [Related]  

  • 15. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
    Negredo E; Miró O; Rodríguez-Santiago B; Garrabou G; Estany C; Masabeu A; Force L; Barrufet P; Cucurull J; Domingo P; Alonso-Villaverde C; Bonjoch A; Morén C; Pérez-Alvarez N; Clotet B;
    Clin Infect Dis; 2009 Sep; 49(6):892-900. PubMed ID: 19663689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Approval of a new nucleoside. Component of complete once daily regimen].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():91. PubMed ID: 15373067
    [No Abstract]   [Full Text] [Related]  

  • 17. ART regimes and fat: the healing hand wielding the sword.
    Domingo P; Espinet J; Vidal F
    Lancet HIV; 2017 Jan; 4(1):e2-e3. PubMed ID: 27815067
    [No Abstract]   [Full Text] [Related]  

  • 18. Nonnucleoside reverse transcriptase inhibitors.
    Murphy RL
    AIDS Clin Care; 1997 Oct; 9(10):75-7, 79. PubMed ID: 11364757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between lipodystrophy and leptin in human immunodeficiency virus-1-infected children receiving lopinavir/ritonavir-based therapy.
    Resino S; Palladino C; Lorente R; Micheloud D; Bellón JM; Larru B; Gutiérrez MD; de José MI; Polo R; Muñoz-Fernández MA;
    Pediatr Infect Dis J; 2010 Aug; 29(8):774-7. PubMed ID: 20375850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disorders of body fat distribution in HIV-1-infected patients.
    Moreno S; Miralles C; Negredo E; Domingo P; Estrada V; Gutiérrez F; Lozano F; Martínez E
    AIDS Rev; 2009; 11(3):126-34. PubMed ID: 19654854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.